Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

286

Participants

Timeline

Start Date

July 24, 2023

Primary Completion Date

December 28, 2027

Study Completion Date

December 28, 2028

Conditions
Cervical Cancer
Interventions
DRUG

Neoadjuvant Therapy

Cisplatin 50 mg/m\^2 d1 q21+ Paclitaxel 175 mg/m\^2 d1 q21+serplulimab 300mg d1 q21

RADIATION

CCRT

weekly cisplatin for 4 or 5 weeks is administered concomitant with EBRT (45-50.4Gy) in 1.8-2 daily fractions and a 10-20 Gy boost to reach a total dose of 65 Gy when there was unresectable lymph nodes.

RADIATION

Brachytherapy

The primary cervical tumor is the boosted, using image guided 3D brachytherapy or 2D brachytherapy, with an additional 30-40 Gy to HRCTV (3D brachytherapy) or to point A (2D brachytherapy), to achieve a total dose of 80 Gy for small-volume cervical tumors or 85 Gy for larger-volume cervical tumors.

Trial Locations (1)

610000

RECRUITING

Sicchuan cancer hospital, Chengdu

All Listed Sponsors
lead

Sichuan Cancer Hospital and Research Institute

OTHER